MedPath

Phase 1 multi-center study of safety and feasibility of chemoradiotherapy using oxydol for cervical cancer

Phase 1
Conditions
cervical cancer
Registration Number
JPRN-UMIN000039045
Lead Sponsor
Juntendo University Urayasu Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

less than 20 years old having distant metastasis

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1 month after treatment completion, 1 year, 2 years overall survival, disease-free survival and progression-free survival
Secondary Outcome Measures
NameTimeMethod
Type, severity, and ratio of adverse events that occurred up to the date of follow-up observation
© Copyright 2025. All Rights Reserved by MedPath